Johnson & Johnson reported strong operational growth and exceeded adjusted earnings expectations despite currency headwinds. Management expressed confidence in continued growth, highlighting successes in pharmaceuticals and accelerating consumer segment performance. The positive outlook and maintained guidance suggest a favorable short-term impact on the stock price.

[1]